The exact role of TRPV1 in the pathogenesis of AD remains controversial, as some studies have reported that TRPV1 activation rescues AD‐related synaptic dysfunction and cognitive deficits,20, 21 while others have shown that upregulation or activation of TRPV1 exacerbates AD pathologies by increasing Aβ and phosphorylated tau levels.22, 23. Here, MAPT is linked to Cognitive impairment.